Here are the 8-K filings from Latigo Biotherapeutics, Inc. (LTGO) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow LTGO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LTGO filings page.
Latigo Biotherapeutics, Inc. reported a third-quarter 2026 net loss of $20.9 million, compared with $24.8 million a year earlier, and cash and cash equivalents of $401.2 million as of September 30, 2026; it expects that balance to fund current operating plans into 2029. Research and development expense was $17.5 million versus $22.1 million, while general and administrative expense was $5.4 million versus $2.6 million.
Todd Smith became president and chief executive officer effective November 3, 2026, replacing Nima Farzan, who resigned from the board. Farzan is to remain an employee through January 1, 2027, unless earlier terminated, then provide consulting services through December 31, 2027, unless earlier terminated. Smith’s package includes a $775,000 annualized salary, a 70% target cash incentive and an option award with a $20 million grant-date fair market value. Options were also approved for Neha Krishnamohan to acquire 175,000 shares and Neil Singla to acquire 350,000 shares, subject to vesting conditions.
Onzotrigine’s Phase 3 bunionectomy and open-label safety trials remain on track for initiation, with topline results expected in the second half of 2027; the bunionectomy study is expected to enroll approximately 480 patients, and Latigo plans to add an oxycodone/acetaminophen comparator arm. LTG-321’s Phase 2 trial is ongoing, with topline results expected in the second half of 2027.
Latigo Biotherapeutics, Inc. (LTGO) reported second-quarter 2026 results and recent business milestones. The company completed an upsized IPO in August 2026, including full exercise of the underwriters’ option, raising $397.4 million in gross proceeds, and expects its cash position, including IPO net proceeds, to fund operations into 2029.
Lead candidate onzotrigine showed positive abdominoplasty trial results published in The New England Journal of Medicine, with plans to start Phase 3 bunionectomy and safety studies in the second half of 2026 and topline data expected in the second half of 2027. Latigo also initiated a Phase 2 trial of LTG-321 in osteoarthritis of the knee and advanced LTG-418 through 14-day non-GLP toxicology studies.
Financially, cash and cash equivalents and restricted cash were $55.2 million as of June 30, 2026. Second-quarter 2026 R&D expenses were $21.2 million versus $22.9 million a year earlier, G&A expenses were $4.6 million versus $2.8 million, and net loss was $25.8 million in both periods.